⁸⁹SrCl₂ and/or Bonefos in the treatment of bone metastasis from pulmonary carcinoma / 中国肺癌杂志

ABSTRACT

<p><b>BACKGROUND</b>To evaluate the effect of ⁸⁹SrCl₂ and/or Bonefos in the treatment of bone metastasis from pulmonary carcinoma.</p><p><b>METHODS</b>A total of sixty-seven lung cancer patients with bone metastasis were enrolled in this study, who were divided into three groups nineteen cases were treated with ⁸⁹SrCl₂; twenty-eight cases with Bonefos; and twenty cases combined ⁸⁹SrCl₂ with Bonefos.</p><p><b>RESULTS</b>The total relief rate of the bone pain the ⁸⁹SrCl₂ group was 84.2%, and the Bonefos group was 80.4%, the combination group was 90.0%. There was no statistical difference among three groups (P > 0.05). The effective rate of the bone metastasis the ⁸⁹SrCl₂ group was 15.7%, the Bonefos group was 10.7%, and the combination group was 45.0%. The combination group had significantly higher effective rate than that of the ⁸⁹SrCl₂ group or the Bonefos group alone (P < 0.05). The rate of improvement of quality of life the ⁸⁹SrCl₂ group was 47.3%, the Bonefos group was 42.8%, and the combination group was 80.0%. The combination group had significantly higher effective rate than that of the ⁸⁹SrCl₂ group or the Bonefos group alone (P < 0.05). The side effects of three groups were minimal.</p><p><b>CONCLUSIONS</b>⁸⁹SrCl₂ and Bonefos are two effective and safe drugs on relief of pain. Combined ⁸⁹SrCl₂ and Bonefos might be a better therapy for bone metastasis and improvement of quality of life than the single one, and the side effect is slight and tolerable.</p>